For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Thiazolidinediones as Therapy for Endometriosis: A Case SeriesMoravek M.B.a · Ward E.A.a · Lebovic D.I.a, b
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology,aUniversity of Michigan, Ann Arbor, Mich. and bUniversity of Wisconsin, Madison, Wisc., USA Corresponding Author
University of Wisconsin, Department of Ob/Gyn
Division of Reproductive Endocrinology and Infertility, H4/628 Clinical Science Center
600 Highland Avenue, Madison, WI 53792-3236 (USA)
Tel. +1 734 262 3990, Fax +1 608 262 9862, E-Mail firstname.lastname@example.org
Background: Current medical therapies for endometriosis result in delayed conception and have not been shown to provide any fertile benefit subsequent to treatment. Thiazolidinediones (TZDs) do not impede conception and have been shown to reduce endometriotic lesions in animal models; however, no studies have been performed in humans. The aim of this study was to provide preliminary data about the effectiveness of a TZD in treating endometriosis-related pain. Methods: Case series of women with endometriosis recruited from the University of Michigan as part of an open-label prospective phase 2a clinical trial. Participants were given rosiglitazone, 4 mg daily, for 6 months. Subjective endometriosis symptoms were assessed using a modified Biberoglu and Behrman symptom severity scale and the McGill pain questionnaire. Results: Two of the 3 patients exhibited improvement in severity of symptoms and pain levels with a concurrent decrease in pain medication, while 1 experienced no change. Rosiglitazone was well tolerated by all patients. Conclusions: Combined with data gathered from studies in rats and nonhuman primates, the results from this study offer positive justification for using TZDs as a well-tolerated treatment for endometriosis that can address pain without impeding ovulation and without the need for add-back therapy.
© 2009 S. Karger AG, Basel